Publikation

A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland

Wissenschaftlicher Artikel/Review - 21.03.2021

Barbier Michaela Carla, Pardo Esther, Panje Cédric, Gautschi Oliver, Lupatsch Judith Eva, Swiss Group for Clinical Cancer Research (SAKK)